Long-Acting Beta Agonists Revised Labeling Warns Of Asthma Death Risk
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis and Schering-Plough are negotiating with FDA over revised labeling for long-acting beta-adrenergic agonist Foradil, according to Novartis